SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VIR

Vir Biotechnology, Inc. (NASDAQ:VIR)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.39-$0.48 (-5.41%)
 
Market cap
$1.44B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 11, 2019
Website
Market Cap$1.44B+37.1%
Revenue (ttm)$302.80M+1696.0%
Net Income-$184.79M+63.0%
EPS-$1.26+65.1%
Shares Out171.27M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,088,951
Open$8.81
Previous Close$8.87
Day's Range$8.35 - $8.91
52-Week Range$5.45 - $14.38
Beta1.74
AnalystsBuy
Price Target$23.50(+180.10%)
Earnings DateFeb 22, 2027

About VIR

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

Address
499 Illinois Street, San Francisco, CA, 94158, US
Market Cap
1.44 billion
Employees
367
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.44M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $20.71 (+146.8%)

4 firms rating VIR in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From VIR’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.41%
5 Days
-14.82%
1 Month
-19.56%
6 Months
-8.71%
1 Year
+37.09%

$VIR stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VIR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VIR's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VIR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

VIR Revenue by Segment or Geography

$91.89MTotal
Personnel$25.80M28.07%
Contract manufacturing$25.75M28.03%
Clinical costs$22.79M24.80%
Other R&D$17.55M19.10%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New VIR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VIR from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VIR

IJRiShares Core S&P Small-Cap ETF$71.68M
VTIVanguard Morningstar Total Stock Market ETF$43.20M
VBVanguard Morningstar Small-Cap ETF$38.51M
IWMiShares Russell 2000 ETF$30.98M
XBIState Street SPDR S&P Biotech ETF$23.15M
VBKVanguard Morningstar Small-Cap Growth ETF$21.60M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VIR’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
58

News check: Positive Phase III data for hepatitis D treatment offset by dilutive $150M share offering and 15% premarket decline.

Recent Insider Activity

Buys
0
Sells
10
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GERMETFMG Treatments, Testing and Advancements ETF2.79%
MOMAGFiQ U.S. Market Neutral Momentum Fund2.26%
IDNAiShares Genomics Immunology and Healthcare ETF1.54%
GNOMGlobal X - Genomics & Biotechnology ETF1.17%
BBCVirtus Biotech Clinical Trials ETF1.13%
WDNAWisdomTree BioRevolution Fund1.10%
PSCHInvesco S&P SmallCap Health Care ETF0.88%
OASCOneAscent Enhanced Small and Mid Cap ETF0.59%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.58%
NIXTResearch Affiliates Deletions ETF0.51%
AESLHarbor AlphaEdge Small Cap Value ETF0.32%
XBIState Street SPDR S&P Biotech ETF0.31%

Weight is the stock’s share of each fund’s holdings.